Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec and Panitumumab in Advanced Squamous Cell Carcinoma of the Skin
NCT04163952Phase 1Terminated
- Sponsor
- Rutgers University
- Start
- Jan 2020
- Primary completion
- Mar 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in squamous cell carcinoma of the skin (SCC), sponsored by Rutgers University. Primary endpoints: Number of Participants With Treatment Related Adverse Events up to 30 days and Response Rate to Panitumumab up to 2 years. Started Jan 2020; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT04163952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163952.